SE-7552

SE-7552, a 2- (difluoromethyl) -1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice[1][2].

Product Specifications

CAS Number

[2243575-79-1]

UNSPSC

12352005

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/se-7552.html

Purity

99.48

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)C(O1)=NN=C1C(C=N2)=CN=C2NC(C)C3=CC=C(F)C=C3

Molecular Formula

C15H12F3N5O

Molecular Weight

335.28

References & Citations

[1]Jason A Holt, et al. SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo. Blood (2018) 132 (Supplement 1) : 3215.|[2]Beate König, et al. 2- (Difluoromethyl) -1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation? ACS Pharmacol. Transl. Sci. 2024, February 20.